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The strategy of antiangiogenic drugs is based on inhibiting formation of new blood vessels as alternative
to limit cancer progression. In this work, we investigated the antitumor and antiangiogenic potential of
eight thalidomide derivatives. Most of the molecules was not cytotoxic but 2a, 2d and 3d revealed weak
antiproliferative activity on HL-60, Sarcoma 180 (S180) and normal peripheral blood mononuclear cells.
Thalidomide, 2a and 2b were able to inhibit tumor growth (53.5%, 67.9% and 67.4%, respectively) in
S180-bearing mice and presented moderate and reversible toxicity on liver, kidneys and spleens. Both
analogs (2a and 2b) inhibited cell migration of endothelial (HUVEC) and melanoma cells
(MDA/MB-435) at 50 lg/mL. Immunohistochemistry labeling assays with CD-31 (PECAM-1) antibody
showed microvascular density (MVD) was signiﬁcantly reduced in thalidomide, 2a and 2b groups
(30 ± 4.9, 64.6 ± 1.8 and 46.5 ± 19.5%, respectively) (p < 0.05). Neovascularization evaluated by
Chorioallantoic Membrane Assay (CAM) with compounds 2a and 2b showed reduction of vessels’ number
(12. 9 ± 2.3 and 14.8 ± 3.3%), neovascularization area (13.1 ± 1.7 and 14.3 ± 1.7%) and total length of ves-
sels (9.2 ± 1.5 and 9.9 ± 1.9%). On the other hand, thalidomide did not alter vascularization parameters.
Consequently, addition of thiosemicarbazone pharmacophore group into the phthalimidic ring improved
the in vivo antitumor and antiangiogenic potential of the analogs 2a and 2b.
Published by Elsevier Ireland Ltd.1. Introduction become activated in numerous illnesses, including ocular and car-Angiogenesis is a complex regulated biological process involved
in the formation of new blood vessels in normal or pathological
conditions [1]. Various regulatory and signaling molecules manage
angiogenesis, including VEGF (vascular endothelial growth factor),
PDGF (platelet-derived growth factor), FGF (ﬁbroblast growth fac-
tor), EGF (epidermal growth factor), HGF (hepatocyte growth
factor), PlGF (placenta growth factor), receptor tyrosine kinases
(RTKs), transcription factors, as well as molecules involved
in MAPK (Mitogen-activated protein kinases) and PI3K
(Phosphatidylinositol 3-kinase) signaling [1,2]. Angiogenic eventsdiovascular diseases, inﬂammation and cancer [3–5].
In cancer, tumor cells stimulate angiogenesis in an effort to
maintain and allow tumor progression. Thus, neovascularization
improves blood supply (oxygen and nutrient) to the neoplasic cells,
and consequently favors the tumor growth [1,3,4,6]. Therefore, the
angiogenesis has become an attractive target in therapeutic
approaches due to its key role in tumor growth, invasion and
metastasis [2,3,6–8].
Thalidomide is the most known angiogenesis inhibitor. It is a
synthetic derivative of glutamic acid with contains two imide
rings: glutarimide and phthalimide. Due to its neurotoxicity, this
drug caused devastating teratogenic effects in the 1960s [9,10].
Nowadays, thalidomide is effective to treat different diseases,
including leprosy, acquired immunodeﬁciency syndrome (AIDS),
Fig. 1. Phthalimide analogs derived from thalidomide used in this study. Analogs
were obtained as demonstrate by Pessoa et al. [17].
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orders [11,12]. Thalidomide is classiﬁed as an immunomodulatory
drug (IMiD) that inhibits the production of tumor necrosis factor
alpha (TNF-a) and may also affect the production of
interleukin-1b (IL-1b), IL-2, IL-4, IL-5, IL-6, IL-10 and interferon-c
(IFN-c). Moreover, secretion of both vascular endothelial growth
factor (VEGF) and beta ﬁbroblast growth factor (bFGF) from tumor
and bone marrow stromal cells is suppressed upon exposure to
IMiDs, resulting in reduced endothelial cell migration and adhesion
[10,11]. The idea of using thalidomide in the cancer treatment
occurred after the discovery of its antiangiogenic properties in
the early 1990s [13]. Despite the thalidomide mechanism in cancer
is not fully understood, its derivatives are known by immunomod-
ulatory and anti-inﬂammatory effects that likely contribute to
antiangiogenic effects [2,14]. In 2006, the Food and Drug
Administration (USA) approved it against multiple myeloma [13].
To overcome risks caused by thalidomide, such as teratogenic-
ity, many analogs have been developed with anticancer proposal.
Previous reports showed that structural variations of thalidomide
could change the side-effect proﬁle, potentially eliminating them,
while still maintaining the desired anticancer activity and demon-
strating promising results in clinical trials [2,10]. Lenalidomide
(Revlimid™) was approved for use in patients with myelodysplas-
tic syndromes (MDS) and multiple myeloma [15]. Pomalidomide is
a potent second-generation IMiD. In vitro studies have shown that
pomalidomide is 10-fold more potent than lenalidomide and up to
15,000 times more potent than thalidomide at inhibiting TNF-a.
Pomalidomide has shown signiﬁcant clinical activity in phase I
and II trials on patients with relapsed and/or refractory multiple
myeloma [16].
In the current study, thalidomide and eight analogs were tested
using in vitro and in vivo assays to assess their performance on
tumor growth inhibition and tumor angiogenesis. Based on the
structure–activity relationship, these novel analogs were devel-
oped with the phthalimide and thiosemicarbazone pharmacophore
groups [17] (Fig. 1). Data presented here add important ﬁndings
about antitumor effects of these analogs on solid tumors.2. Materials and methods
2.1. Materials
Phthalimide derivatives (2a–f and 3a–b) were synthesized as
described by Pessoa et al. [17]. Purity of compounds was provided
by elemental analysis data.
Primary antibody CD-31 (Platelet Endothelial cell Adhesion
Molecule-1, PECAM-1) and secondary antibody were purchased
from Santa Cruz Biotechnology. Anti-VEGF monoclonal antibody
(Bevacizumab – Avastin™) Genentech/Roche, CA, USA) was pur-
chased from Santa Cruz Biotechnology. Endothelia basal medium
(EBM), RPMI 1640 medium, fetal bovine serum (FBS), peni-
cillin/streptomycin and glutamine were purchased from Gibco
(USA). Alamar Blue™, 5-Fluorouracil (5-FU), hydrocortisone, gen-
tamicin and mitomycin C were obtained from Sigma Aldrich (St.
Louis, MO, USA). All the other chemicals were of analytical grade
and used as indicated by manufacturer. Thalidomide tablets
100 mg were used (FUNED, MG, Brazil). All molecules were diluted
in DMSO to a ﬁnal concentration of 5 mg/mL (stock solution).
Chemical names and purity data of all compounds tested are given
in Supplementary material.2.2. Animals
Adult female Swiss mice (Mus musculus Linnaeus, 1758) were
obtained from the animal facilities at Universidade Federal doCeará (UFC), Fortaleza, Ceará, Brazil. They were kept in
well-ventilated cages under standard conditions of light (12 h with
alternate day and night cycles) and temperature (22 ± 2 C) and
were housed with free access to commercial rodent stock diet
(Nutrilabor, Campinas, Brazil). Ross chicken eggs of the Gallus
domesticus species weighing 50 g, 12–24 h after laid, were pur-
chased from CIALNE™ Company (Fortaleza, Ceará, Brazil) and
stocked for 24 h at 19–20 C before incubation. All procedures
were approved by the Committee on Animal Research at UFC
(Process n 106/2007) and they are in accordance with the
Brazilian (COBEA – Colégio Brasileiro de Experimentação Animal)
and International Standards on the care and use of experimental
animals (Directive 2010/63/EU of the European Parliament and of
the Council).
2.3. Cytotoxicity assays
Cytotoxic potential of the compounds (thalidomide, 2a–2f, 3a,
3b) was assessed after 72 h exposure using cancer cell lines
[HL-60 (leukemia), HCT-8 (colon), MDA/MB-435 (melanoma) and
SF-295 (glioblastoma)], Sarcoma 180 cells (S180) and normal
peripheral blood mononuclear cells (PBMC). Human cell lines were
maintained in RPMI 1640 medium supplemented with fetal bovine
serum 10%, 100 U/mL penicillin/streptomycin at 37 C with 5% CO2
atmosphere. In similar conditions, S180 tumor cells and PBMC
were cultured in RPMI 1640 medium supplemented with 20% fetal
bovine serum. Quantiﬁcation of cell proliferation was determined
spectrophotometrically using a multiplate reader (DTX 880
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the same amount of dimethylsulfoxide (DMSO 0.1%).
2.3.1. Evaluation of the cytotoxicity on tumor cell lines
In vitro antiproliferative activity against four human tumor cell
lines (HL-60, HCT-8, MDA-MB-435 and SF-295) was determined by
MTT assay, a cell viability assay that detect reduction of a yellow
dye 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide (MTT) to a blue formazan product [18]. Brieﬂy, cells were
plated in 96-well plates (0.1–0.3  106 cells/mL) to allow adhesion.
After 24 h, thalidomide and its analogs (0.78–100 lg/mL) were
added to each well. Doxorubicin (0.005–5 lg/mL) was used as pos-
itive control. After 69 h of incubation, plates were centrifuged and
the medium was replaced by fresh medium (150 lL) containing
MTT (0.5 lg/mL). Three hours later, plates were centrifuged, and
the formazan was dissolved in DMSO. The effect of the molecules
was quantiﬁed at 595 nm.
2.3.2. Evaluation on PBMC proliferation
Heparinized human blood (from healthy, non-smoker donors
who had not taken any drug for at least 15 days prior to sampling,
aged between 18 and 35 years) was collected and PBMC were iso-
lated by a standard method of density-gradient centrifugation over
Ficoll-Hypaque. PBMC were washed and resuspended in supple-
mented RPMI 1640 medium and phytohemagglutinin (3%). Then,
PBMC were plated in 96-well plates (5  105 cells/well in 100 lL
of medium). After 24 h, compounds (0.78–100 lg/mL) were added
to each well and cells were incubated during 72 h. Twenty-four
hours before the late incubation, 10 lL of stock solution
(0.312 mg/mL) of Alamar Blue™ were added to each well [19].
Doxorubicin (0.005–5 lg/mL) was used as a positive control. The
effect was quantiﬁed as the percentage of control absorbance at
570 nm and 595 nm. These studies were performed in accordance
to the Brazilian research guidelines (Law 466/2012, National
Council of Health, Brazil) and the Declaration of Helsinki.
2.3.3. Evaluation on proliferation of Sarcoma 180 cells
Ascite-bearing mice between 7 and 9 days post inoculation
were sacriﬁced by cervical dislocation and a suspension of S180
cells was harvested from the intraperitoneal cavity under aseptic
conditions. The suspension was centrifuged at 500g for 5 min to
obtain a cell pellet and washed 3 times with RPMI medium. Cell
concentration was adjusted to 0.5  106 cells/mL in supplemented
RPMI 1640 medium, plated in a 96-well plate and incubated with
increasing concentrations of the compounds (0.4–100 lg/mL). Cell
proliferation was determined by the Alamar Blue assay after 72 h
[20]. Eight hours before the late incubation, 10 lL of stock solution
(0.312 mg/mL) of Alamar Blue™ were added to each well. The
absorbance was measured at 570 nm and 595 nm and the antipro-
liferative effect was quantiﬁed as percentage of the control.
2.4. In vivo antitumor assay
Female Swiss mice (20–25 g) obtained from the facilities of the
Federal University of Ceará were used. Animals were kept in cages
with free access to food and water under a 12/12 h light–dark cycle
(lights on at 6:00 a.m.). Sarcoma 180 cells were maintained in the
peritoneal cavities of the mice. Ten-day-old sarcoma 180 ascite
tumor cells were removed from the peritoneal cavity, counted
and subcutaneously implanted into the right hind axillary of the
animals (4  106 cells/mL). In the following day, thalidomide and
its analogs (50 mg/kg/day) dissolved in DMSO 10% were intraperi-
toneally administered for 7 days. Negative and positive controls
received DMSO 4% and 5-FU (25 mg/kg/day), respectively. On the
8th day, mice were sacriﬁced and tumors, livers, spleens and kid-
neys were dissected out, weighed and ﬁxed in 10% formaldehyde.The inhibition ratio of tumor growth (%) was calculated as follows:
inhibition ratio (%) = [(A  B)/A]  100, where A is the average
tumor weight in the negative control, and B is the average in each
separately treated group.
2.4.1. Histopathology and morphological observations
Tumors, livers, spleens and kidneys ﬁxed with formaldehyde
were grossly examined for size or color changes and hemorrhage.
Subsequently, these structures were cut into small pieces to pre-
pare histological sections (4–7 lm) and stained with hematoxylin
and eosin (H&E). Histological analyses were performed under light
microscopy.
2.5. Antiangiogenic assays
2.5.1. Migration assay
The migration assay, also called Wound Healing Assay, was per-
formed as previously described by Bürk [21] with some modiﬁca-
tions. HUVEC and MDA-MB-435 cells were used in this test. The
human umbilical vascular endothelia cells (HUVEC-CC2517) was
cultured in endothelia basal medium (EBM) supplemented with
20% FBS, human epidermal grow factor (hEGF) 10 lg/mL, hydro-
cortisone 1 mg/mL, gentamicin 50 mg/mL, bovine brain extract
3 mg/mL (BBE) and used at early passages. These cells were incu-
bated at 37 C with 5% CO2 atmosphere. For this, HUVEC-CC2517
cells were cultured until a conﬂuent monolayer formed (>90%)
and MDA/MB-435 cells (2  105 cells/mL) were both cultured in
12 well plates. After conﬂuence, each well was treated with mito-
mycin C (5 lg/mL) for 15 min. Wells were washed with PBS and
appropriated medium was added. Using a sterile plastic pipette
tip, a wound was made in the center of the plate by the removal
of the cell monolayer [22]. After washing, cells were incubated
with a nontoxic dose of thalidomide and analogs (2a and 2b,
50 lg/mL). Negative control of both cells was treated only with
culture medium and vehicle (DSMO). After 24 h of incubation,
the wells were visualized and photographed using inverted micro-
scope (Nikon, UK, magniﬁcation of 200) to observe cellular
migration through the wound.
2.5.2. Assessment of angiogenesis by immunohistochemistry
In order to verify pathways involved on inhibiting neovascular-
ization, the same in vivomodel of the antitumor activity evaluation
was used to quantify intratumoral vessels staining with CD-31
(PECAM-1) antibody. To assess the antiangiogenic potential, the
treatment with thalidomide and its analogs (2a and 2b) were
started after 5 days of inoculation of Sarcoma 180 cells and
extended for 10 consecutive days at 50 mg/kg/day. Negative and
positive controls received 10% DMSO and 5-FU (25 mg/kg/day),
respectively. Additionally, the monoclonal antibody bevacizumab
(5 mg/kg/day) was used as standard drug. For each group of ani-
mals, chosen tumors were those that apparently had a larger num-
ber of peri- and intra-tumoral vessels.
Histological image samples were acquired under light micro-
scope (BX4, Olympus Optical Co. Ltd., Japan) using a digital camera
(C7070 Wide Zoom, Olympus Imaging America Inc., USA). The pro-
cedure included an initial scan of the tumor at 40 magniﬁcation
in order to identify areas with increased vascular density called
‘hot spots’. Three hot spots selected for each tumor were
color-scanned at magniﬁcation of 200. Images were saved as
Windows bitmaps (512  384 pixels since 1 pixel = 24 bits, RGB
color scheme). Morphometric analyses of slides were processed
by the System Quantiﬁcation of Angiogenesis (SQAN), software
speciﬁcally developed for this purpose [23]. The system was previ-
ously adjusted to the color spectrum produced by the staining
techniques employed. This step enabled the software to automati-
cally identify and segment (single out) blood microvessels in both
Table 1
In vitro cytotoxic activity of thalidomide and its synthetic analogs on tumor cell lines evaluated by the MTT and on primary culture of Sarcoma 180 and peripheral blood
mononuclear cells (PBMC) quantiﬁed by Alamar Blue assay after 72 h of incubation.
Compound CI50 (lg/mL)
MDA-MB-435 HCT-8 SF-295 HL-60 Sarcoma 180 PBMC
2a >100 >100 74.3 (49.0–75.0) 72.0 (39.6–96.6) >100 >100
2b >100 >100 >100 >100 >100 >100
2c >100 >100 >100 >100 >100 >100
2d >100 >100 >100 58.6 (52–65.3) 11.3 (7.8–16.5) >100
2e >100 >100 >100 >100 >100 >100
3a >100 >100 >100 >100 >100 >100
2f >100 >100 >100 >100 >100 >100
3b >100 >100 >100 >100 >100 26.6 (19.6–30.9)
Thalidomide >100 >100 >100 40.3 (30.3–54) >100 90.7 (83.6–98.6)
Doxorubicin 0.8 (0.8–1.6) 0.8 (0.8–1.6) 1.9 (1.5–2.0) 1.6 (0.8–1.6) 0.3 (0.2–0.5) 0.9 (0.5–1.8)
Data are presented as IC50 values and 95% conﬁdence intervals for leukemia (HL-60), melanoma (MDA/MB-435), colon (HCT-8) and glioblastoma (SF-295) human tumor lines
and for primary culture of Sarcoma 180 and peripheral blood mononuclear cells. Doxorubicin was used as positive control. All in vitro studies were carried out in triplicate
represented by three independent biological evaluations.
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mentation (making changes in segmentation parameters)
remained an option whenever the automatic mode was deemed
inadequate. After the segmentation, the software provided the
microvascular density of areas studied. The area density was
obtained by dividing the area of microvasculature by the total area
analyzed [24].
2.5.3. In vivo chorioallantoic membrane (CAM) assay
To evaluate the activity of thalidomide and its synthetic analogs
(2a and 2b) on the blood vessels’ formation, the chorioallantoic
membrane (CAM) assay was used [25,26]. Brieﬂy, eggs were incu-
bated in a hatcher at 38.5 C under a humidiﬁed atmosphere (33%
relative humidity) and with rotary movement every 2 h. After 72 h
of incubation (embryonic day – E3 stage 20-HH; Hamburger and
Hamilton [27]), a hole in the eggshell (approximately 100 mm2)
was done until reach the air camera, causing a displacement
between the inner shell membrane and vitelline membrane. The
albumin was withdrawn using a sterile syringe through a hole
made on the opposite side. Subsequently, eggs were sealed and
re-incubated. At day 10 of incubation, eggs (n = 8) were treated
with ﬁlter paper disk (2 mm) impregnated with 20 lL of thalido-
mide and analogs (1 e 5 mg/mL) and these disks were implanted
over the chorioallantoic membrane. Negative control was treated
with 10% DMSO. After treatment, the eggshell window was sealed
and eggs were re-incubated at 38.5 C. At 12th day of incubation,
eggs were removed from the incubator. A solution of white ink
in distilled water (2:1) was injected within the allantoic sac and
a white background was obtained underneath the treatment disks.
Antiangiogenic response was determined by the number of blood
vessels around the disk, and expressed as percent of vessels in
the limit of the disk. For this, digital images of the CAM were stan-
dardized in four quadrants (top, bottom, right and left) correspond-
ing to the region around the ﬁlter paper disk containing the tested
compounds. Images acquired were analyzed by the System
Quantiﬁcation of Angiogenesis (SQAN) as described above [24].
The parameters analyzed for angiogenesis quantiﬁcation included
area of neovascularization, vascular length and total number of
blood vessels.
2.6. Statistical analysis
For cytotoxicity studies, IC50 values and their 95% conﬁdence
intervals were obtained by nonlinear regression. All in vitro studies
were carried out in triplicate represented by independent biologi-
cal evaluations. In order to determine differences among treat-
ments, data expressed as mean ± standard error of the mean(S.E.M.) were compared by one-way analysis of variance
(ANOVA) followed by the Newman–Keuls test (p < 0.05) using the
Graphpad program (Intuitive Software for Science, San Diego, CA).3. Results
3.1. In vitro antiproliferative action
Outcomes revealed that none of the studied molecules showed
potent cytotoxic action on tumor lines (HL-60, HCT-8,
MDA-MB-435 and SF 295). In vitro weak antiproliferative activity
was found in HL-60-treated cells with 2a [72.0 (39.6–
96.6) lg/mL], 2d [58.6 (52–65.3) lg/mL] and thalidomide
[40.3 (30.3–54) lg/mL] (Table 1).
To evaluate in vitro cytotoxic activity on primary cell cultures,
the Alamar Blue™ assay was used. Once again, majority of the
molecules showed weak action on sarcoma 180 and polymorphic
blood mononuclear cells, and compounds 2d and 3b exhibited
IC50 values of 11.3 (7.8–16.5) lg/mL and 26.6 (19.6–30.9) lg/mL
on sarcoma and PBMC, respectively.
3.2. Evaluation of the antitumor activity of thalidomide and its analogs
in mice
The evaluation of the antitumor activity of thalidomide and its
analogs was performed in Sarcoma 180-bearing mice. Thalidomide
(0.98 ± 0.15 g), 5-FU (0.34 ± 0.04 g), compound 2a (0.67 ± 0.12 g)
and compound 2b (0.69 ± 0.09 g) reduced tumor growth
(53.5 ± 7.2, 83.9 ± 2.3, 67.9 ± 6.0 and 67.4 ± 4.6%, respectively)
when compared to negative control (2.11 ± 0.18 g) (p < 0.05)
(Table 2).
3.2.1. Tumor morphological alterations
Analysis of the tumor tissue showed polygonal and mitotic cells,
cellular pleomorphism and presence of anisokaryosis in all groups
(Fig. 2). Areas of coagulative necrosis and hemorrhage were espe-
cially seen in 5-FU, 2a and 2b-treated groups (Fig. 2B–D).
Changes about relative weight of the livers and kidney were not
noticed (Table 2). On the other hand, 2b and 3b-treated groups
showed a signiﬁcantly increasing in their spleen relative weights
in comparison with the control group (0.73 ± 0.05, 0.82 ± 0.08
and 0.55 ± 0.05 g, respectively) (p < 0.05) while positive control
treated with 5-FU suffered from a reduction in the relative weight
of this organ (0.22 ± 0.01 g). Kidneys showed glomerular and inter-
stitial hemorrhage and presence of hyaline cylinders in all groups,
especially in 2e-treated mice, which also showed intense cellular
Table 2
Effect of thalidomide and its synthetic analogs (50 mg/kg/day) on tumor growth in Swiss mice bearing Sarcoma 180 after 7 days of treatment.
Treatment Dose (mg/kg/day) Mice weight (g) Liver Kidney Spleen Tumor mass (g) Tumor inhibition (%)
g/100 g body weight
Negative control – 31.38 ± 1.25 5.26 ± 0.14 1.38 ± 0.03 0.55 ± 0.05 2.11 ± 0.18 –
5-FU 25 24.60 ± 0.40* 4.86 ± 0.27 1.28 ± 0.03 0.22 ± 0.01* 0.34 ± 0.04* 83.9 ± 2.3*
Thalidomide 50 29.00 ± 0.94 4.93 ± 0.09 1.38 ± 0.02 0.46 ± 0.03 0.98 ± 0.15* 53.5 ± 7.2*
2a 50 29.38 ± 0.82 5.20 ± 0.16 1.50 ± 0.06 0.49 ± 0.03 0.67 ± 0.12* 67.9 ± 6.0*
2b 50 30.33 ± 0.76 5.13 ± 0.16 1.42 ± 0.04 0.73 ± 0.05* 0.69 ± 0.09* 67.4 ± 4.6*
2c 50 29.77 ± 1.83 5.47 ± 0.12 1.32 ± 0.04 0.54 ± 0.05 1.66 ± 0.35 28.9 ± 16.6
2d 50 29.67 ± 1.40 5.30 ± 0.16 1.40 ± 0.08 0.51 ± 0.02 1.74 ± 0.28 17.9 ± 12.5
2e 50 30.50 ± 0.89 5.67 ± 0.24 1.39 ± 0.06 0.69 ± 0.05 1.69 ± 0.22 20.1 ± 10.6
2f 50 30.00 ± 0.00 5.94 ± 0.21 1.43 ± 0.07 0.69 ± 0.05 1.90 ± 0.16 10.4 ± 7.6
3a 50 30.50 ± 1.16 6.03 ± 0.33 1.42 ± 0.09 0.71 ± 0.06 1.68 ± 0.19 20.6 ± 8.9
3b 50 31.43 ± 0.92 5.94 ± 0.26 1.39 ± 0.05 0.82 ± 0.08* 1.49 ± 0.28 29.6 ± 13.1
Values are means ± S.E.M., n = 10 animals/group. Negative control was treated with the vehicle used to dilute the drug (10% DMSO). 5-Fluorouracil (5-FU) was used as positive
control.
* p < 0.05 compared with the negative control by ANOVA followed by Newman–Keuls test.
Fig. 2. Histotological analyses by light microscopy of tumors in sarcoma-180 bearing mice intraperitoneally treated with thalidomide and its analogs during 7 days. Negative
control was treated with the vehicle used for diluting the tested substances (DMSO 10%). (A) Control (DMSO 10%); (B) 5-Fluouracil (5-FU) (25 mg/kg/day); (C) 2a (50 mg/
kg/day); (D) 2b (50 mg/kg/day); (E) Thalidomide (50 mg/kg/day). Hematoxylin–eosin staining. Magniﬁcation, 400.
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ation. Histological structure of the spleen did not reveal micro-
scopic changes. In general, many megakaryocytes and preserved
architecture of the white and red pulp were observed, even in
the 2b and 3b groups. In 2e and 2f groups, light congestion anddisorganization in the red pulp were noted. Hemosiderin pigments
were also found. Hyperplasia of the hepatic Kupffer cells, inﬂam-
matory foci and focal microvesicular steatosis were exhibited in
all treated and untreated animals. Intense cellular swelling and
necrosis areas were observed in the 2e group. However, all samples
P.M. da Costa et al. / Chemico-Biological Interactions 239 (2015) 174–183 179analyzed suggested preservation of the hepatic parenchyma and
glomerular architecture.
3.3. Antiangiogenic potential
The most active analogs against in vivo tumor (2a and 2b) were
selected to execute detailed studies about the mechanism of
action.
3.3.1. Cell migration inhibition
In order to assess the inhibitory effect of analogs, in vitro assays
were carried out to verify the ability to inhibit HUVEC and
MDA-MB-435 migration (Fig. 3). Both analogs (2a and 2b) inhib-
ited cell migration at a concentration of 50 lg/mL, leading to the
migration inhibition of 65.3 ± 1.6 and 65.2 ± 2.4% on endothelial
cells and 23.8 ± 0.8 and 98.5 ± 0.3% of inhibition on melanoma cells
(Fig. 4). Thalidomide was not able to reduce cell migration.
3.3.2. Tumor angiogenesis inhibition analyzed by
immunohistochemistry
Antitumor activity of thalidomide, 2a and 2b (50 mg/kg/day)
was also performed to determine tumor vasculature related
parameters. The treatment started at 5th day after the Sarcoma
180 tumor inoculation and was performed for 10 consecutive days.
Subsequently, the animals were sacriﬁced on the 15th day and
tumors were dissected out. Thalidomide (2.29 ± 0.13 g) and ana-
logs (2a: 2.73 ± 0.59 g; 2b: 3.09 ± 0.49 g) reduced tumor growth
(56.6 ± 6.5, 48.2 ± 11.2 and 41.4 ± 9.4%, respectively) in comparison
with negative control (5.28 ± 0.71 g) (p < 0.05) (Table 3). Only
thalidomide-treated animals presented weight loss in the posterior
treatment (29.14 ± 1.16 g) compared to control (34.08 ± 1.25 g)
(p < 0.05). Fig. 5A shows a tumor section, indicating vessels andFig. 3. Effects of thalidomide and its analogs on the migration of human umbilical vein en
incubation. Each well was pretreated with mitomycin C (5 lg/mL) for 15 min. (A) Nega
(50 lg/mL). Magniﬁcation, 100. Studies were carried out in triplicate represented by tcells immunostained with CD-31 antibody.
Immunohistochemistry assays showed that microvascular density
(MVD) was signiﬁcantly reduced in thalidomide, 2a and 2b groups
(30 ± 4.9, 64.6 ± 1.8 and 46.5 ± 19.5%, respectively) in comparison
with negative control group (Fig. 5B) (p < 0.05).3.3.3. Angiogenesis assay in the chorioallantoic membrane (CAM) of
chicken embryo
To evaluate the in vivo antitumor effect of thalidomide and ana-
logs, the chorioallantoic membrane assay, also known as in ovo
chicken embryo method, was performed in attempt to correlate
the inhibition of vessel formation with antitumor potential.
Compounds 2a and 2b (5 mg/mL) were able to reduce number of
vessels (12. 9 ± 2.3 and 14.8 ± 3.3%), neovascularization area
(13.1 ± 1.7 and 14.3 ± 1.7%) and the total length of vessels in
mm2 (9.2 ± 1.5 and 9.9 ± 1.9%) as shown in Fig. 6. Thalidomide,
on the other hand, did not alter these vascularization parameters.
Concentration dependent analyzes are in progress in attempt to
observe pharmacological outcomes and possible toxic effects.4. Discussion
In the ﬁght against cancer, search for new chemical entities
(NCEs) with chemotherapeutic properties is really worthy and
numerous methods have been utilized to acquire compounds,
including isolation from plants and animals and the use of syn-
thetic and combinatorial chemistry and molecular modeling
[19,28–31]. Thalidomide, for example, was the ﬁrst drug with sig-
niﬁcant clinical outcomes against multiple myeloma (MM) and can
be considered as alternative treatment for patients treated with
conventional therapy or after transplantation [32]. Beneﬁts of
thalidomide for MM patients may be due to its ability to inhibitdothelial cells (HUVEC) and melanoma cells (MDA/MB-435) before and after 24 h of
tive control (DMSO 0.1%); (B) Thalidomide (50 lg/mL); (C) 2a (50 lg/mL); (D) 2b
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Fig. 4. Effects of thalidomide (Thl) and analogs (2a and 2b) analyzed by the Wound
Healing Assay measured after 24 h of incubation. (A) Human umbilical vein
endothelial cells (HUVEC); (B) Melanoma cells (MDA-MB-435). Negative control (C)
was treated with the vehicle used for diluting the tested substances (DMSO 0.1%).
Results are mean ± S.E.M. of two independent experiments performed in triplicate
obtained by cells counting that invaded the scar. *p < 0.05 compared to negative
control by ANOVA test followed by Newman–Keuls test.
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observed in different tumor types. Due to this potential, chemical
modeling of the thalidomide is a source of novel precursors with
therapeutic properties. Taking into consideration structure–activ-
ity related studies (SAR), analogs and metabolites of thalidomide
clearly showed that the presence of the pharmacophoric unit
phthalimide is essential for its pharmacological activity [33].
Thiosemicarbazone was another important pharmacophoric group
used in this study. The anticancer effects of thiosemicarbazones
and its analogs (semicarbazones and N-acyl-hydrazones) have
been quite promising, acting on cell proliferation and combating
chemotherapy resistances [34].Table 3
Effect of thalidomide and synthetic analogs (50 mg/kg/day) on tumor growth in Swiss
mice bearing Sarcoma 180. The treatment started after 5 days of Sarcoma 180
inoculation and extended for 10 consecutive days.
Treatment Dose
(mg/kg/day)
Mice
weight (g)
Tumor (g) Tumor
inhibition (%)
Negative control – 34.08 ± 1.25 5.28 ± 0.71 –
5-FU 25 30.63 ± 1.21 3.09 ± 0.41* 41.5 ± 7.8*
Thalidomide 50 29.14 ± 1.16* 2.29 ± 0.13* 56.6 ± 2.5*
2a 50 31.43 ± 0.75 2.73 ± 0.59* 48.2 ± 11.2*
2b 50 31.86 ± 1.24 3.09 ± 0.49* 41.4 ± 9.4*
Values are means ± S.E.M., n = 10 animals/group. Negative control was treated with
the vehicle used to dilute the drug (10% DMSO). 5-Fluorouracil (5-FU) was used as
positive control.
* p < 0.05 compared with the negative control by ANOVA followed by Newman–
Keuls test.Herein, the cytotoxic analyses of eight phthalimide and
thiosemicarbazone analogs were performed by the MTT and
Alamar Blue™ assays, revealing weak in vitro antitumor activity
against tumor cells. Thus, the addition of the thiocarbonyl group
to the phthalimide ring did not improve the cytotoxic action.
However, compound 2d showed promising action on sarcoma
180 cells. Previously, a series of 16 novel thalidomide sulfur ana-
logs containing one and two sulfur atoms were screened for
in vitro antitumor activity against Ehrlich ascites carcinoma cell
line and also exhibited potent cytotoxic action [35]. A relationship
between the thiosemicarbazone subunit and antiproliferative
effects on experimental tumors has been established, since this
chemical structure inhibits ribonucleotide reductase processes,
alters DNA structure, presents chelating capacity with potent and
selective antineoplasic activity and generates iron complexes with
redox activity [34,36,37].
In vitro effects can be not directly extrapolated for in vivo mod-
els. Thus, evaluating the pharmacological actions of these com-
pounds in complete biological systems becomes an obligatory
requirement. In order to assess the in vivo antitumoral action, the
compounds were evaluated using the Sarcoma 180 experimental
model, a mouse-derived tumor widely exploited in antitumor
research [20,38–40]. In Sarcoma-180-bearing animal assays, only
thalidomide and compounds 2a and 2b revealed antitumor action.
Interestingly, the compound 2d was not able to inhibit in vivo
tumor growth, though it has displayed moderate in vitro cytotoxi-
city against Sarcoma 180 cells. Probably, in vivo metabolic activa-
tion is required to generate compounds with antiproliferative
effect on solid tumors as seen with thalidomide, 2a and 2b.
It has been demonstrated that inhibition of angiogenesis and
tumor growth by thalidomide or analogs requires metabolic acti-
vation [12,41–43]. In a similar way, Pessoa et al. [17] also suggest
that a prior metabolic activation is necessary to produce one or
more active metabolites from N-phthaloyl amino acids derivatives,
explaining their antiproliferative activity on in vivo models only.
Therefore, it is also possible that the metabolizing of the molecules
also explains, at least in part, the in vivo antitumor action, since it is
very known that some molecules undergo hepatic enzymatic reac-
tions to generate active metabolites [44]. Zahran et al. [35], using
an in vivo model of experimental carcinoma, also demonstrated
that thalidomide dithiocarbamate and dithioate analogs have
activity against Ehrlich carcinoma-induced solid tumor in Swiss
albino mice.
Histopathological analyses of livers in treated animals showed
Kupffer cell hyperplasia, microvesicular steatosis and preserved
hepatic parenchyma. The liver possesses a pronounced regenera-
tive capacity: even when necrosis is found with conjunctive tissue
preservation, there is often complete tissue restoration [44]. Thus,
hepatic alterations observed in 2a and 2b treated groups were
reversible.
In spite of only compounds 2a and 2b have exhibited antitumor
action, both 2b and 3b caused spleen enlargement, a ﬁnding sug-
gestive of immunostimulant action of these molecules. Indeed,
immunomodulatory drugs based on thalidomide, mainly
amino-substituted thalidomide analogs, have been reported to be
superior candidates as antitumor agents [45,46]. Despite thalido-
mide had not led to spleen morphological alterations in this work,
it is known that some phthalimide analogs are co-stimulatory sub-
stances, increasing the response of T-lymphocytes to
T-cell-receptor-mediated stimulation, the production of
interleukin-2 and interferon-c as well as the number of natural
killer cells [17,47]. On the other hand, most clinical chemotherapy
drugs are immunosuppressive and has negative side effects [48],
such as leucocyte suppression, hypoplasia of the splenic white pulp
and small lymphoid aggregates in 5-FU-treated mice [46]. These
ﬁndings display the importance about enhancement of host
AC 5-FU Thl 2a 2b
0
2
4
6
8
10
M
ic
ro
v
as
c
u
la
r 
de
ns
ity
(%
)
50 mg/kg/day25 mg/kg/day
*
*
B
Fig. 5. Effects on tumor angiogenesis evaluated by immunohistochemistry. (A) Images of a hot spot on the tumor obtained by inverted microscope and processed by the
System Quantiﬁcation of Angiogenesis (SQAN). White arrows indicate vessels and cells immunostained with CD-31 (PECAM-1) antibody (Magniﬁcation, 200); (B) Effects of
thalidomide (Thl) and analogs (2a and 2b) on microvascular density analyzed by immunohistochemistry in Sarcoma 180 tumors after 10 days of treatment started after on
the 5th inoculation day. Negative control (C) was treated with the vehicle used to dilute the drug (DMSO10%). 5-Fluorouracil (5-FU) was used as positive control. Values are
mean ± S.E.M. Microvascular density of areas was analyzed in 3 slides/group. *p < 0.05 compared with the negative control by ANOVA followed by Newman–Keuls test.
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chemotherapy since it involves slight side effects.
In general, the in vivo antitumor effect of thalidomide is not
commonly observed in the literature. Gutman et al. [49], testing
the efﬁcacy of thalidomide daily administered by gavage (0.3–
1.0 mg until 10 days), reported no growth retardation in CT-26
bearing mice nor in mice with pulmonary or peritoneal metastases
of B16-F10 melanoma. On the other hand, antitumor effects of
thalidomide have been associated with its antiangiogenic proper-
ties. It is well known that new analogs of thalidomide, including
the second generation, have a great therapeutic potential.
Therefore, these novel and active pharmacologically compounds
were divided into two classes: SelCIDs (selective cytokine inhibi-
tory drugs) and IMiDs (immunomodulatory drugs) [50].
In order to evaluate the antiangiogenic potential of the mole-
cules 2a and 2b, antiangiogenic assays were performed. Cell migra-
tion technique has been widely used as a screening assay for newcompounds with antiangiogenic activity [51,52]. Both molecules
(2a and 2b) that showed promising in vivo results inhibited cell
migration of endothelial (HUVEC) and melanoma cells
(MDA-MB-435) at 50 lg/mL. On the other hand, thalidomide was
not able to reduce cell migration, whose inefﬁcacy can be
explained by the fact that thalidomide requires metabolic activa-
tion to produce one or more active metabolites after incubation
with microsomal proteins, as previously described [12,53]. These
data suggested that the absence of migration was not caused by
cytotoxicity or inhibition of proliferation and other factors are
probable involved in the antiangiogenic potential, a ﬁnding that
needs to be investigated.
The continuous growth of tumors requires oxygen and nutrients
and these substances are provided by the blood ﬂow. In vivo
antiangiogenic action of the compounds were performed in
Sarcoma 180-bearing mice assay with a longer period of exposure
(10 days) since effects of antiangiogenic therapy cannot be
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Fig. 6. Effects of thalidomide (Thl) and analogs (2a and 2b) on embryonic
angiogenesis analyzed by the in ovo Chorioallantoic Membrane Assay (CAM) after
24 h exposure. (A) Number of vessels; (B) Neovascularization area; (C) Total length
of the vessels. Graphs were obtained by the software SQAN from the average of the
four quadrants photographed in a stereoscopic microscope (BX4, Olympusb Optical)
equipped with a digital camera (C7070 Wide Zoom, Olympus). Negative control (C)
was treated with the vehicle used for diluting the tested substances (DMSO 0.1%).
Studies were carried out in triplicate represented by two independent biological
evaluations. Values are mean ± S.E.M. *p < 0.05 compared with the negative control
by ANOVA followed by Newman–Keuls test.
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labeling was determined. CD-31 or PECAM-1 is an adhesion mole-
cule present in endothelial cells and platelets. It is a member of the
immunoglobulin superfamily expressed on the surface of endothe-
lial cells, platelets, monocytes, neutrophils and T cells [55–58].
Thalidomide and analogs (2a and 2b) inhibited tumor growth but
intratumor vessels stained with the CD-31 antibody revealed
reduction in microvascular density (MVD) only in 2a and 2b
groups.
In vivo chorioallantoic membrane (CAM) assay demonstrated
effects of molecules on the neovascularization. The results con-
ﬁrmed that only compounds 2a and 2b were able to reduce the
number of vessels, neovascularization area and the total length
of vessels at 5 mg/mL after 24 h exposure. These ﬁndings indicate
that addition of the thiosemicarbazone pharmacophore group tothe phthalimidic ring in thalidomide increased its antitumor
potential and angiogenesis activity. Thalidomide, on the other
hand, did not change vascularization parameters probably because
in vivo hepatic biotransformation is necessary [12,53]. In fact,
thalidomide antiangiogenic activity is signiﬁcantly increased by
human microsomal activation, but different ﬁndings are observed
in rats. It is known that hydroxylation of thalidomide in positions
10 and 50 keep its antiangiogenic potential, but the hydroxylation
at 40 position generates an inactive compound [59].5. Conclusions
The addition of thiosemicarbazone pharmacophore group into
the phthalimidic ring improved the in vivo antitumor and antian-
giogenic potential of the analogs 2a and 2b. These molecules have
special interest for the development of new anticancer therapies
and additional studies are in progress to elucidate the mechanism
of action of these bioactive phthalimides.Conﬂict of Interest
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